A Phase 1 interventional study of GRT6019 in Duchenne Muscular Dystrophy (DMD), sponsored by Grünenthal GmbH. Completed at 1 site in France. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Muscular Dystrophy, Duchenne with a site in France — 11 open to participants now, 13 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · France.
Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, this one is the 37th largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2026, is one of 4 in phase 1, and was the 63rd registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →11 of the 66 studies in Muscular Dystrophy, Duchenne with a site in France are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in France, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Nantes University Hospital · Sites in France
Ages 5–60 · Men only · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 2+ · Healthy volunteers
Assistance Publique Hopitaux De Marseille · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 16 · Phase 3 24
First in 2006; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is close to the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 83 across the 50 interventional studies, 220 across the 15 observational. Of the 46 that completed or were terminated, 18 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 66 have an industry lead sponsor. The 10 most frequent:
Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
Grünenthal GmbH has 3 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
2 of the studies in Muscular Dystrophy, Duchenne with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833489Assistance Publique Hopitaux De MarseilleTranscriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases | 2026-12-01 |
| NCT06147414Assistance Publique - Hôpitaux de ParisDevelopment of Non-Invasive Prenatal Diagnosis for Single Gene Disorders | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to assess the safety, tolerability, and PK of 3 doses of GRT6019 in healthy male participants.
This Phase I trial will be a multiple dose trial in healthy male participants with administration of GRT6019 in 3 cohorts.
For each participant, the trial consists of a Screening Period of up to 28 days, a 4 week Treatment Period (including a 2-week clinic stay and 2 weeks in an outpatient setting), and a 5 week Follow-up Period.
There are 8 participants planned per cohort to ensure sufficient sample size for a reliable estimate of PK parameters.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 weeks dosing with GRT6019 low dose once a day \[QD\]
Drug: GRT6019
4 weeks dosing with GRT6019 medium dose once a day \[QD\]
Drug: GRT6019
4 weeks dosing with GRT6019 higher dose once a day \[QD\]
Drug: GRT6019
Multiple dose (MD)
Number of participants with Adverse Events (AEs)
Assessment of safety and tolerability of GRT6019 following 4 weeks of treatment
Time frame: Through study completion, an average of 4 Weeks
Number of participants with Serious Adverse Events (SAEs)
Assessment of safety and tolerability of GRT6019 following 4 weeks of treatment
Time frame: Through study completion, an average of 4 Weeks
Number of participants with AEs leading to discontinuation
Assessment of safety and tolerability of GRT6019 following 4 weeks of treatment
Time frame: Through study completion, an average of 4 Weeks
Number of participants with AEs related to investigational medicinal product [IMP]
Assessment of safety and tolerability of GRT6019 following 4 weeks of treatment
Time frame: Through study completion, an average of 4 Weeks
Area under the concentration-time curve over the dosing interval (AUCtau)
Assessment of the pharmacokinetics (PK) of GRT6019 following 4 weeks of treatment, including dose proportionality assessment and investigation of steady state attainment
Time frame: Following the first dose (Day 1), then at Day 14, and after the last dose (Day 28)
Maximum observed concentration (Cmax)
Assessment of the pharmacokinetics (PK) of GRT6019 following 4 weeks of treatment, including dose proportionality assessment and investigation of steady state attainment
Time frame: Following the first dose (Day 1), then at Day 14, and after the last dose (Day 28)
Plan to share: No
Ran from Jan 2026 to primary completion in Jun 2026, 5 months.
Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegacorat
Muscular Dystrophy, Duchenne →